{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-014859","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2023-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.562829+00:00","generated_at":"2026-06-16T04:22:16.477606+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arrowhead Q2 net income $48.7M ($0.45 diluted); milestones from Takeda, GSK, positive ARO-RAGE data","bullets":["Revenue $146.3M, operating income $48.2M, net income $48.7M ($0.45 diluted), up from $44.4M ($0.41) in prior year.","Earned $40M milestone from Takeda for fazirsiran Phase 3 start; $30M from GSK for Phase 2b of GSK4532990 (NASH).","Phase 1/2 ARO-RAGE: mean max 80% reduction in serum sRAGE after two 92 mg doses; no serious AEs; supports lung delivery platform.","Regained rights to ARO-PNPLA3 from Janssen; FDA Fast Track for ARO-APOC3 for familial chylomicronemia syndrome.","Cash and investments $559.8M vs $482.3M at Sept 30, 2022; R&D Day June 1, 2023; ARO-SOD1 on track for Q3 CT filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-014859","json":"https://secwatch.observer/filing/0001628280-23-014859.json","markdown":"https://secwatch.observer/filing/0001628280-23-014859.md","text":"https://secwatch.observer/filing/0001628280-23-014859.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000162828023014859/0001628280-23-014859-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000162828023014859/arwr-20230502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T04:22:16.477606+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6a9703948bde18717f39beaa32314eddff3074d9","claim":"ARROWHEAD PHARMACEUTICALS, INC. reported its fiscal second quarter ended March 31, 2023 results: revenue $ 146,267, net income $ 48,675, EPS $ 0.45.","evidence_excerpt":"in The New England Journal of Medicine Selected Fiscal 2023 Second Quarter Financial Results Three Months Ended March 31, OPERATING SUMMARY 2023 2022 (unaudited) Revenue $ 146,267 $ 151,805 Operating Expenses: Research and development 74,881 75,985 General and administrative expenses 23,221 34,267 Total Operating Expenses 98,102 110,252 Operating income","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/879407/000162828023014859/0001628280-23-014859-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"its fiscal second quarter ended March 31, 2023"},{"label":"Revenue","value":"$ 146,267"},{"label":"Net income","value":"$ 48,675"},{"label":"EPS","value":"$ 0.45"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}